These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12234297)

  • 1. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.
    Slatopolsky E; Cozzolino M; Finch JL
    Kidney Int; 2002 Oct; 62(4):1277-84. PubMed ID: 12234297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
    Takahashi F; Finch JL; Denda M; Dusso AS; Brown AJ; Slatopolsky E
    Am J Kidney Dis; 1997 Jul; 30(1):105-12. PubMed ID: 9214408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
    Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
    J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D analogs for the treatment of secondary hyperparathyroidism.
    Slatopolsky E; Brown AJ
    Blood Purif; 2002; 20(1):109-12. PubMed ID: 11803167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone.
    Finch JL; Brown AJ; Slatopolsky E
    J Am Soc Nephrol; 1999 May; 10(5):980-5. PubMed ID: 10232683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
    Slatopolsky E; Finch J; Ritter C; Takahashi F
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of 22-oxacalcitriol on serum calcitriol.
    Dusso AS; Negrea L; Finch J; Kamimura S; Lopez-Hilker S; Mori T; Nishii Y; Brown A; Slatopolsky E
    Endocrinology; 1992 Jun; 130(6):3129-34. PubMed ID: 1597134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia.
    Slatopolsky E; Finch J; Ritter C; Denda M; Morrissey J; Brown A; DeLuca H
    Am J Kidney Dis; 1995 Nov; 26(5):852-60. PubMed ID: 7485144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E; Cozzolino M; Lu Y; Finch J; Dusso A; Staniforth M; Wein Y; Webster J
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect.
    Lippuner K; Perrelet R; Casez JP; Popp A; Uskokovic MR; Jaeger P
    Horm Res; 2004; 61(1):7-16. PubMed ID: 14646396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between vitamin D deficiency and phosphorus depletion in the rat.
    Brautbar N; Walling MW; Coburn JW
    J Clin Invest; 1979 Feb; 63(2):335-41. PubMed ID: 219035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats.
    Wu-Wong JR; Nakane M; Chen YW
    Life Sci; 2013 Feb; 92(2):161-6. PubMed ID: 23261531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport.
    Brown AJ; Finch J; Slatopolsky E
    J Lab Clin Med; 2002 May; 139(5):279-84. PubMed ID: 12032488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.
    Wu-Wong JR; Noonan W; Ma J; Dixon D; Nakane M; Bolin AL; Koch KA; Postl S; Morgan SJ; Reinhart GA
    J Pharmacol Exp Ther; 2006 Jul; 318(1):90-8. PubMed ID: 16603671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.
    Cozzolino M; Lu Y; Finch J; Slatopolsky E; Dusso AS
    Kidney Int; 2001 Dec; 60(6):2109-17. PubMed ID: 11737585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.
    Frazão JM; Elangovan L; Maung HM; Chesney RW; Acchiardo SR; Bower JD; Kelley BJ; Rodriguez HJ; Norris KC; Robertson JA; Levine BS; Goodman WG; Gentile D; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
    Am J Kidney Dis; 2000 Sep; 36(3):550-61. PubMed ID: 10977787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
    Coyne DW; Grieff M; Ahya SN; Giles K; Norwood K; Slatopolsky E
    Am J Kidney Dis; 2002 Dec; 40(6):1283-8. PubMed ID: 12460048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.